{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:07:11Z","timestamp":1790687231407,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.nmd.2022.04.003","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T21:19:42Z","timestamp":1649798382000},"page":"451-459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Longer-term follow-up of nusinersen efficacy and safety in adult patients with spinal muscular atrophy types 2 and 3"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3870-1035","authenticated-orcid":false,"given":"Yaara","family":"Fainmesser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian E","family":"Drory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Ben-Shushan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Lavon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luba","family":"Spector","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Abramovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2022.04.003_bib0001","series-title":"Spinal muscular atrophy","author":"Lunn","year":"2008"},{"issue":"2","key":"10.1016\/j.nmd.2022.04.003_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1016\/j.nmd.2022.04.003_bib0003","doi-asserted-by":"crossref","DOI":"10.1111\/ene.13534","article-title":"Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c\u20134","volume":"25","author":"Wadman","year":"2018","journal-title":"Eur J Neurol"},{"issue":"9","key":"10.1016\/j.nmd.2022.04.003_bib0004","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000324623.89105.c4","article-title":"Natural history of SMA IIIb: muscle strength decreases in a predictable sequence and magnitude","volume":"71","author":"Deymeer","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.nmd.2022.04.003_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2014.01.003","article-title":"Hammersmith functional motor scale and motor function measure-20 in non ambulant SMA patients","volume":"24","author":"Mazzone","year":"2014","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.nmd.2022.04.003_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2015.10.006","article-title":"Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"10.1016\/j.nmd.2022.04.003_bib0007","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-008-0929-0","article-title":"A natural history study of late onset spinal muscular atrophy types 3b and 4","volume":"255","author":"Piepers","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2022.04.003_bib0008","doi-asserted-by":"crossref","DOI":"10.1038\/nrneurol.2018.4","article-title":"Advances in therapy for spinal muscular atrophy: promises and challenges","author":"Groen","year":"2018","journal-title":"Nature Rev Neurol"},{"issue":"18","key":"10.1016\/j.nmd.2022.04.003_bib0009","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.nmd.2022.04.003_bib0010","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.nmd.2022.04.003_bib0011","article-title":"Evidence in focus: nusinersen use in spinal muscular atrophy report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology","volume":"91","author":"Michelson","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.nmd.2022.04.003_bib0012","article-title":"AVXS-101 (Onasemnogene Abeparvovec) for SMA1: comparative study with a prospective natural history cohort","volume":"6","author":"Al-Zaidy","year":"2019","journal-title":"J Neuromuscul Dis"},{"issue":"3","key":"10.1016\/j.nmd.2022.04.003_bib0013","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00415-020-10223-9","article-title":"Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4","volume":"268","author":"De Wel","year":"2020","journal-title":"J Neurol [Internet]"},{"issue":"11","key":"10.1016\/j.nmd.2022.04.003_bib0014","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","article-title":"Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3","volume":"91","author":"Maggi","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.nmd.2022.04.003_bib0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol [Internet]"},{"issue":"2","key":"10.1016\/j.nmd.2022.04.003_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/mus.26769","article-title":"Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience","volume":"61","author":"Veerapandiyan","year":"2020","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.nmd.2022.04.003_bib0017","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-019-0998-4","article-title":"SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy","volume":"14","author":"Pechmann","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"10.1016\/j.nmd.2022.04.003_bib0018","doi-asserted-by":"crossref","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2022.04.003_bib0019","unstructured":"Finkel R.S., Sejersen T., Mercuri E., Bertini E., Chen K., Crawford T.O., et al. 218th ENMC International Workshop:: Revisiting the consensus on standards of care in SMA Naarden, The Netherlands, 19\u201321 February 2016. In: neuromuscular Disorders. 2017."},{"issue":"14","key":"10.1016\/j.nmd.2022.04.003_bib0020","doi-asserted-by":"crossref","first-page":"e1988","DOI":"10.1212\/WNL.0000000000010540","article-title":"Muscle strength and motor function in adolescents and adults with spinal muscular atrophy","volume":"95","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2022.04.003_bib0021","article-title":"Revised Hammersmith scale for spinal muscular atrophy","volume":"25","author":"Ramsey","year":"2015","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.nmd.2022.04.003_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172346","article-title":"Revised Hammersmith Scale for spinal muscular atrophy: a SMA specific clinical outcome assessment tool","volume":"12","author":"Ramsey","year":"2017","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.nmd.2022.04.003_bib0023","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2022.04.003_bib0024","article-title":"Nusinersen treatment of older children and adults with spinal muscular atrophy","author":"Konersman","year":"2020","journal-title":"Neuromuscul Disord [Internet]"},{"issue":"13","key":"10.1016\/j.nmd.2022.04.003_bib0025","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008166","article-title":"Long-term progression in type II spinal muscular atrophy: a retrospective observational study","volume":"93","author":"Mercuri","year":"2019","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.nmd.2022.04.003_bib0026","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1111\/ene.14472","article-title":"Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy","volume":"27","author":"Stolte","year":"2020","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2022.04.003_bib0027","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-017-0853-y","article-title":"A qualitative study of perceptions of meaningful change in spinal muscular atrophy","volume":"17","author":"McGraw","year":"2017","journal-title":"BMC Neurol"},{"issue":"3","key":"10.1016\/j.nmd.2022.04.003_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2014.11.008","article-title":"Upper limb module in non-ambulant patients with spinal muscular atrophy: 12 month changes","volume":"25","author":"Sivo","year":"2015","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.nmd.2022.04.003_bib0029","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense Oligonucleotide Therapies:the Promise and the Challenges from a Toxicologic Pathologist's Perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.nmd.2022.04.003_bib0030","unstructured":"FDA. Nusinersen BLA. 2015; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/207958Orig1s000ChemR.pdf"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896622001109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896622001109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:11:55Z","timestamp":1760775115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896622001109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0960896622001109"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2022.04.003","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longer-term follow-up of nusinersen efficacy and safety in adult patients with spinal muscular atrophy types 2 and 3","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2022.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}